Applications of (S)-(+)-4-Amino-3-Hydroxybutanoic Acid in Industrial Manufacturing

(S)-(+)-4-Amino-3-Hydroxybutanoic Acid supports advanced synthesis workflows and precise production needs in several tightly regulated industries. As a dedicated chemical raw material manufacturer, we ensure traceable production, batch consistency, and compliance at every stage. Below, we detail its core functions and integration in real downstream sectors.

1. Chiral Intermediate for Antiepileptic Pharmaceutical Manufacturing

Pharmaceutical manufacturers use (S)-(+)-4-Amino-3-Hydroxybutanoic Acid as a key chiral intermediate in the synthesis of antiepileptic active ingredients, such as the enantiomerically pure forms required for specific drug approvals. Integration into the API synthesis chain requires absolute stereochemical purity and robust traceability from source material to final formulation. Users incorporate the raw material during early or mid-stage condensation steps, under controlled temperature and pH, to build critical nonracemic centers in the final molecule. The acid ensures proper orientation and consistency to meet regulatory scrutiny for APIs commercialized under strict patents and global distribution approvals.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• Ph. Eur., USP, and JP monographs as required for final API
• FDA 21 CFR Part 210/211 (for US-distributed products)
• EU EudraLex Volume 4 GMP requirements for intermediates

Typical usage ratio

• 0.6–0.9 molar equivalents relative to total substrate, based on final batch size and target enantiomeric excess; adjusted for reaction yield and desired purity level

Downstream process integration

• Enters API synthesis at the stereoselective amination or cyclization step after initial precursor preparation
• Requires careful pH control and solvent compatibility for maximum yield
• In-process checks at each stage to ensure chiral purity

Final product types

• Antiepileptic tablets (e.g., Levetiracetam enantiomers, Brivaracetam derivatives)
• Custom chiral APIs for investigational neurological treatments
• Intermediates for further modification in contract drug synthesis

2. Stereochemically Pure Building Block in Peptide Synthesis

Peptide manufacturers utilize the acid for custom peptide assembly, capitalizing on its distinct stereochemistry. It acts as a protected amino acid analog, introduced at defined chain growth stages to impart specific biological or physicochemical properties to the peptide product. Operators dissolve the acid in polar solvents and couple it with other protected amino acids via solution-phase or solid-phase peptide synthesis (SPPS) protocols. Batch traceability and enantiomeric control are vital for medical-grade or research-grade peptide lots, especially those supplied into therapeutic or diagnostic chains.

Industry compliance standards

• ISO 9001:2015 for quality management in manufacturing peptides
• ISO 13485 (for components in diagnostic peptide products)
• GMP guidelines where final product enters clinical or therapeutic use
• Certificate of Analysis specifying enantiomeric excess & impurity profile

Typical usage ratio

• 1–3 mmol per peptide synthesis cycle, proportional to target peptide sequence; actual amount adjusted for resin loading in SPPS and coupling efficiency

Downstream process integration

• Substituted during chain extension, between standard amino acids, in SPPS reactors or solution-phase vessels
• Subjected to Fmoc/Boc protection protocols as needed
• Monitored by HPLC and optical rotation for sequence fidelity

Final product types

• Research-grade bioactive peptides
• Diagnostic kit peptide components
• Therapeutic peptides with custom backbone features

3. Precursor for Synthesis of Enantiopure GABA Analogues

The acid functions as a precursor in the manufacture of enantiomerically pure gamma-aminobutyric acid (GABA) analogues. Downstream specialty chemical producers employ it as an initial feedstock for chemical transformations including reduction, acylation, or lactam formation, generating high-value GABA derivatives designed for pharmaceutical or research uses. Reaction parameters involve controlled hydrogenation and protection/deprotection steps to retain stereo-integrity and avoid by-product formation. Regular chiral HPLC checks and batch documentation protect downstream producers’ commercial interests and compliance status.

Industry compliance standards

• REACH compliance for chemical intermediates in Europe
• ISO 14001 environmental management (for process waste handling)
• CGMP as referenced in final API chain (if GABA analog enters medicinal use)
• Controlled Substance precursor tracking (as per national regulations, if required)

Typical usage ratio

• Varies 1–1.2 equivalents to desired GABA analogue output, fine-tuned by process yield and desired product purity

Downstream process integration

• Introduced at the first or second synthetic stage, where chiral skeleton formation is critical
• Subjected to reductive conversion or acyl derivatization
• Requires in-process chiral profiling and impurity monitoring

Final product types

• GABA-based antispasticity or neuroprotective compounds
• Reference standards for analytical laboratories
• Chiral specialty chemicals for chemical biology research

4. Ingredient for Nutraceutical and Dietary Supplement Research Formulations

Research-driven nutraceutical developers and functional food technologists assess (S)-(+)-4-Amino-3-Hydroxybutanoic Acid for potential inclusion in cognitive support and neuro-regulative supplement prototypes. Its direct use is subject to jurisdictional review, mainly in pre-clinical or pilot batches intended for proof-of-concept or market evaluation. Developers incorporate the material in blends for encapsulation, evaluating stability, bioavailability, and interaction with other active compounds. Real-time QC is mandatory at each mixing and tableting step, influenced by dietary supplement GMP and food additive safety frameworks.

Industry compliance standards

• US FDA 21 CFR Part 111 (Dietary Supplement GMPs)
• EFSA Novel Food Regulations (if applicable in EU)
• China’s National Food Safety Standard for New Food Raw Materials
• ISO 22000 food safety management (for large-scale ingredient blending)

Typical usage ratio

• 10–50 mg per daily serving in R&D batches, adjusted during toxicological review and pre-market assessment; final ratios must remain within jurisdictional regulatory thresholds

Downstream process integration

• Added as an ingredient at the dry blending stage or premix tanks before compressing into tablets/capsules
• Subjected to analytical test for identity, residual solvent, and microbiological safety
• QC includes heavy metals and purity profiles aligned to food supplement criteria

Final product types

• Investigational cognitive support tablets
• Prototype dietary supplement capsules for clinical pilots
• Nutraceutical blends for functional food brands (pre-market, research only)